Exact Sciences Corporation is a global leader in cancer diagnostics and screening, focused on preventing, detecting, and treating cancer through innovative molecular diagnostic solutions. Founded in 1995 in Marlborough, Massachusetts, the company has grown to employ approximately 6,500 people and operates in over 120 countries. Its mission emphasizes early cancer detection and prevention, guided by core values of innovation, integrity, quality, teamwork, and accountability.
The company offers a diverse range of cancer diagnostic tests, including Cologuard®, a non-invasive stool DNA test for colorectal cancer, and the Oncotype DX Breast Recurrence Score® test for genomic assessment. Recent additions to their portfolio include the OncoExTra® cancer therapy selection test and a Multi-cancer Earlier Detection (MCED) test. Exact Sciences has expanded its capabilities through strategic acquisitions, enhancing its personalized cancer diagnostics and broadening its test offerings. Headquartered in Madison, Wisconsin, the company is committed to advancing cancer care and has been recognized as a Great Place To Work for seven consecutive years.
Developer and manufacturer of comprehensive genomic profiling products intended to help physicians make more informed care decisions. The company offers a comprehensive genomic profiling analysis of the tumour genome to identify clinically relevant alterations, thereby potentially expanding patients' treatment options.
Operator of a genomic medicine delivery company intended to bridge the gap between genome technology and current medical practice. The company connects individuals and health care providers to genetic experts, providing a genetic assessment to individuals regarding the benefits of testing and creating a personalized clinical action plan, enabling patients to make informed treatment decisions at low costs and medical practitioners to accelerate disease diagnosis.
Developer of precision medicine in oncology designed to provide big data analysis in cancer. The company develops a cell-free liquid biopsy technology, enabling healthcare professionals to use minimally-invasive molecular diagnosis for treatment selection, therapy monitoring, and detection of cancer earlier.